509 results about "IV Chemotherapy" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention relates to a core-shell structure drug-loaded magnetic-thermal hydrogel microsphere for treating drug-resistant ovarian cancer and a preparation method thereof, belonging to the field of biological and medical micro-nano materials and technologies, and the core-shell structure drug-loaded magnetic-thermal hydrogel microsphere is formed by combining an inner core and a shell layer through covalent crosslinking and electrostatic interaction. An anti-tumor drug cis-platinum and magnetic nanoparticles are loaded on an inner core, and an AZ191 inhibitor is loaded on a chitosan shell, so that preferential release of AZ191 is realized to inhibit a drug-resistant signal channel and reduce the drug resistance of cancer cells, and the cis-platinum is slowly released after the action is completed to kill tumor cells. And the magnetic nanoparticles in the inner core can be heated under an external magnetic field, so that multifunctional synergistic treatment of magnetic hyperthermia, drug resistance inhibition and chemotherapy is realized. Chitosan and sodium alginate are biodegradable materials, so that the utilization rate of the embedded medicine can be increased, and meanwhile, the medicine can be metabolized out of a body. The preparation method does not relate to toxic cross-linking agents and organic solvents, and the prepared hydrogel core-shell microspheres have no biotoxicity. Complicated operation steps are not needed, the technological process is simple, the preparation period is short, and the application range is wide.

A hybrid liver cancer prognosis model, prognosis system and medium, the model takes independent influence factors as input and outputs hybrid liver cancer postoperative risk scores, the hybrid liver cancer postoperative risk scores are used for dividing risk levels, and the risk levels are used for hybrid liver cancer prognosis evaluation. And / or is used for postoperative adjuvant chemotherapy decision-making of mixed liver cancer. The hybrid liver cancer prognosis model is jointly constructed by combining the traditional clinical pathological characteristics and immune microenvironment indexes, the key effect of the tumor immune microenvironment in CHC prognosis is indicated, and the constructed hybrid liver cancer prognosis model has good CHC prognosis prediction performance; in addition, decisions of postoperative adjuvant chemotherapy can be provided for patients with different risk levels, precise treatment of the CHC patients is achieved, and long-term survival prognosis of the CHC patients is improved.

The invention discloses a gastric cancer postoperative chemotherapy dynamic intervention method and system based on time point matching, and relates to the technical field of postoperative intervention. Health state data of wearable medical equipment of a gastric cancer postoperative patient is collected; preliminarily dividing the stomach cancer postoperative chemotherapy cycle into a plurality of key physiological time points based on the symptom inflection points, and respectively matching an intervention core problem and a corresponding stomach cancer postoperative chemotherapy intervention scheme for the plurality of key physiological time points; and the postoperative intervention platform analyzes the time period health state data collected by the wearable medical equipment at set time intervals, analyzes the health state data to automatically identify gastric cancer postoperative symptom inflection points, and dynamically matches key physiological time points based on symptom inflection point results. The stomach cancer postoperative treatment disruption rate is reduced, the crisis inflection point recognition accuracy is greatly improved, and the bone marrow suppression early diagnosis rate is greatly improved; the early diagnosis rate of postoperative wound infection of gastric cancer is improved, unnecessary intervention is reduced, and crisis event treatment is accelerated.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a scrophularia ningpoensis extract for relieving chemotherapy-induced acute kidney injury and application of the scrophularia ningpoensis extract in preparation of a product for relieving chemotherapy-induced acute kidney injury. The preparation method comprises the following steps: putting fresh ginseng into a high-temperature and high-pressure sterilization pot, steaming at 110-120 DEG C for 1-3 hours, taking out, cooling to room temperature, and repeating the steaming cooling process for 2-5 times; and crushing the treated ginseng materials, adding a mixed strain of saccharomyces cerevisiae and lactobacillus plantarum in a mass ratio of 1: 1, fermenting for 24-72 hours, filtering fermentation liquor, and drying filter residues to obtain the black ginseng extract. The cisplatin-induced acute kidney injury is prevented and / or treated by improving oxidative stress and mitochondrial functional activity, reducing the content of lipid peroxide, inhibiting expression of inflammatory factors TNF alpha, IL1beta and COX2 and remarkably reducing the cell apoptosis rate and the level of inflammatory factors related to endoplasmic reticulum stress.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention provides a multifunctional intelligent anti-thrombus PICC (peripherally inserted central catheter) for tumor chemotherapy, which comprises a catheter body, a catheter tip, a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity, and the first auxiliary cavity and the second auxiliary cavity are arranged around the main infusion cavity to form a spiral structure; a micro pressure sensor array is embedded in the pipe wall of the first auxiliary cavity; a biological impedance measuring electrode pair is embedded in the pipe wall of the second auxiliary cavity; and the micro pressure sensor array, the biological impedance measuring electrode pair, the micro ultrasonic transducer and the temperature sensor are connected with a processor. According to the method, active thrombus prevention is achieved, passive treatment is changed into active prevention through a triple mechanism, and the thrombus occurrence rate is greatly reduced; meanwhile, the tube body is formed by mutually winding, fusing and extruding three independent cavities (a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity) like a DNA double helix (triple helix is provided herein); and the mechanical stimulation and damage to the inner wall of the blood vessel are reduced.

The invention relates to a gastric cancer chemotherapy benefit prediction analysis method and system, and the method comprises the steps: obtaining clinical chemotherapy index data, imaging data and basic index data, and carrying out the standard integration processing, and obtaining a clinical integrated data set; carrying out image structure and basic target extraction on the clinical integrated data set to obtain an image structured feature vector and target feature data; obtaining knowledge graph data, and performing association analysis on the knowledge graph data and the target feature data to obtain a corresponding initial scheme group; performing trend prediction on the clinical integration data set according to the dynamic monitoring data to obtain corresponding dynamic trend information; inputting a preset four-factor joint prediction model to perform effect trend prediction to obtain a corresponding benefit prediction result; and performing overall analysis on the initial scheme group and the benefit prediction result to obtain a corresponding overall benefit information report. According to the method, the data basic integrity of benefit prediction can be improved, and more reliable data support is provided for subsequent analysis.

The invention discloses an esophageal cancer local chemotherapy device, and belongs to the technical field of chemotherapy auxiliary equipment, the esophageal cancer local chemotherapy device comprises a sealing device, the sealing device comprises a drug delivery tube, the lower end of the drug delivery tube is fixedly connected with a zigzag mounting tube, and the side wall of the zigzag mounting tube is rotatably connected with a plurality of hinge connecting rods; the lower end of the zigzag mounting tube is fixedly connected with a closed collecting film fixedly connected with the upper ends of the hinge connecting rods, the interior of the zigzag mounting tube is slidably connected with a movable block, and the device can be tightly attached to the inner wall of the esophagus through unfolding of the closed collecting film to form an effective closed structure, so that the position of medicine at the focus is locked, and the medicine is prevented from being damaged. Therefore, the local treatment effect of the medicine can be improved, meanwhile, the medicine is prevented from flowing to the stomach along with natural physiological movement of the esophagus, stimulation to the digestive tract of a patient is reduced, meanwhile, the influence on normal tissue of the patient is reduced, precise treatment is achieved, and the health of the patient is protected to the maximum extent.

Disclosed herein are methods of treating an individual having a gastroesophageal cancer, of treating or identifying an individual having gastroesophageal cancer for a treatment, or stratifying individuals having a gastroesophageal cancer for a treatment based on a tumor mutational burden (TMB) score or a TMB score.

The invention discloses a culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system comprises: a basic culture medium, which is a DMEM / F12 culture medium, and is additionally added with a special growth promoting factor obtained from a natural extract; the multiple growth factors comprise an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a bone morphogenetic protein (BMP) and a vascular endothelial growth factor receptor inhibitor (VEGFRi), and the concentration of each growth factor is accurately screened and optimized; the extracellular matrix is Matrigel modified by physical and chemical methods; the specific additive comprises an antioxidant N-acetylcysteine (NAC). According to the culture system, the culture method and the application of the gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system which is closer to a real environment in vivo is constructed by optimizing basic culture medium components, setting various growth factors and specific additive concentrations and adopting modified Matrigel as an extracellular matrix.

The invention relates to the technical field of gastrointestinal tumor chemotherapy risk assessment, and particularly discloses a gastrointestinal tumor chemotherapy risk scoring model and a construction method thereof, and the method comprises the steps: obtaining the individualized feature data and basic physiological data of a historical patient, and constructing an individualized difference library with a unique ID, and a core influence library; the method comprises the following steps: standardizing and coding double-library data, synchronizing clinical data containing treatment effect codes, forming a data dictionary, acquiring and coding current gastrointestinal tumor patient data, and matching the data dictionary to judge individual difference abnormity; when the first data set is abnormal, constructing a first data set, screening core independent variables through Logistic regression, and constructing a scoring model by using an LSTM (Long Short Term Memory) model; when no abnormity exists, redundant codes are removed to obtain a second data set, and modeling is conducted through the same method. Through double-library linkage and scene-divided modeling, the three-level toxicity risk prediction precision is improved, data support is provided for clinical chemotherapy dose adjustment and toxicity prevention, and the risk of excessive treatment or insufficient treatment is reduced.

The invention provides a solid-liquid phase-change microcapsule cooling cold cap for preventing alopecia in chemotherapy. The solid-liquid phase-change microcapsule cooling cold cap comprises a shell layer, a phase-change cooling layer and a heat-conducting attaching layer, the phase change cooling layer is sealed between the heat conduction bonding layer and the shell layer; the phase change cooling layer comprises a frame and phase change microcapsules; the frame is built between the shell layer and the heat-conducting laminating layer, and the phase change microcapsules are filled between the shell layer and the heat-conducting laminating layer; the phase change microcapsule is a microcapsule encapsulated by a low-temperature solid-liquid phase change material; the solid-liquid phase change material is used as a cooling material, the cooling effect is remarkable, the solid-liquid phase change material is not particularly hard after being frozen, still has a certain deformation space and can be attached to all parts of the head of a patient, medical silica gel is used as the scalp attaching layer, the scalp attaching layer is soft, breathable and good in heat conduction and scalp attaching effect, and the cooling effect is good. The cold cap and the head of the patient are attached more tightly, and the phenomenon that a gap exists between the cold cap and the scalp, and the head anti-falling effect is affected after chemotherapy is avoided.

The utility model belongs to the technical field of medical equipment, and discloses a vomiting relieving treatment device for tumor chemotherapy, which comprises a massage module, a fastening mechanism is arranged on the outer wall of the massage module, and a rolling mechanism is arranged on the outer wall of the massage module; the winding mechanism comprises a winding drum, a partition plate is fixedly connected to the inner wall of the winding drum, a rotating shaft is elastically connected to the outer wall of the partition plate through a volute spiral spring, a clamping groove is formed in the outer wall of the rotating shaft, a fixing block is fixedly connected to the outer wall of the front end of the winding drum, and a limiting block is elastically connected to the inner wall of the fixing block through a connecting spring. The pull-out length of the bandage can be fixed through clamping connection of the limiting block and the clamping groove, limiting of the rotating shaft is removed when the bandage is not used, the bandage can be automatically wound in the winding barrel, space is saved, and the problems that the bandage is wound disorderly due to the fact that the bandage is exposed all the time, and the bandage is inconvenient to tidy in the using process are solved.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and / or have relapsed or not responded to a prior chemotherapy.

The invention relates to a tirapazamine-loaded phosphorus-containing dendrimer / protein compound for inducing tumor mineralization as well as a preparation method and application thereof, the compound takes diphosphonate-terminated phosphorus-containing dendrimer AK176 as a carrier, and the carrier is loaded with protein and medicine. The nano-drug can target tumor cells through FN and form a biomineralization layer in the peripheral area of tumor tissues, and a tumor hypoxic microenvironment is intensified, so that the pharmaceutical activity of tirapazamine is activated, and cooperative treatment of blocking treatment / chemotherapy of triple-negative breast cancer is realized.

The present invention provides a cold-stimulus-resistant nursing device after tumor chemotherapy, belonging to the field of nursing appliances. It includes a wrapping member; a heat-conducting pipe is arranged inside the wrapping member, and heat-generating devices are movably connected to both ends of the heat-conducting pipe. The heat-generating device includes an outer housing, and a blowing structure and a heat-adjusting structure are respectively arranged inside the outer housing. A leak-proof structure is connected between the heat-conducting pipe and the outer housing; the blowing structure includes a central shaft rod rotatably connected to the axis of the outer housing, a variable-frequency motor is fixedly connected inside the outer housing, and an output end of the variable-frequency motor is fixedly connected with a first bevel gear. This application can meet the use of people with different heights, generate heat quickly at the same time, form a circulating heating, the heat in each area is more uniform, and the heat can be automatically adjusted according to the wind speed, and the sealing effect of the structure at the connection between the outer housing and the heat-conducting pipe can be automatically adjusted according to the wind speed.

The invention relates to the technical field of biomedical materials, in particular to a solid-liquid two-phase embolism agent with a surface cilium structure and a preparation method thereof. Comprising an oil-phase liquid embolism material and a Janus cilia microsphere with a hydrophilic cilia structure, the oil-phase liquid embolism material is wrapped by the Janus cilia microspheres, and during wrapping, hydrophilic cilia structures in the Janus cilia microspheres are outwards exposed in a water phase, so that the surface of the solid-liquid dual-phase embolism agent has cilia structures; the cilia structure can improve the interaction force between embolism material particles and between the embolism material particles and a blood vessel wall, has excellent viscoelasticity and deformability, can reach finer artery blood vessels, realizes efficient thick and thin artery embolism, and improves the tumor embolism chemotherapy efficiency; the cilia structure is combined with a solid-liquid two-phase system, so that the embolism effect is improved, the stability of the embolism agent is enhanced, the action time is prolonged, the biocompatibility is optimized, and the application prospect is wide.

The medicine injection equipment is characterized in that the medicine injection equipment comprises a blocking catheter and a medicine injection catheter, the blocking catheter comprises an inner tube and an outer tube, the two ends of the outer tube are sealed, and the inner tube is connected into the outer tube in a penetrating mode; the medicine injection catheter is slidably connected into the inner tube; an infusion tube and a blocking tube are arranged between the inner tube and the outer tube; a front balloon and a rear balloon are arranged on the periphery of the outer tube at intervals, and the blocking tube is communicated with the two balloons; the outer tube is provided with a first medicine injection port between the two balloons, and the infusion tube is communicated with the first medicine injection port; the outer tube is provided with a blood inlet on the front side of the front balloon, a first blood outlet on the rear side of the rear balloon, and a second blood outlet between the front balloon and the rear balloon; a first valve is arranged at the blood inlet and only allows a medium to flow into the blood inlet unidirectionally; under the condition that the equipment can enter a target blood vessel, the efficiency and accuracy of medicine injection can be improved, normal flowing of blood is not affected in the process that the equipment enters the blood vessel, and blood diversion and blocking can be avoided.

An air bag is arranged on the inner side, close to the end, of an infusion tube body, the infusion tube body is sleeved with a liquid medicine spraying bag, a liquid medicine cavity is formed in the liquid medicine spraying bag, a solid latex head is fixedly installed at the end of the infusion tube body, and a liquid medicine catheter pagoda connector is connected with the side edge of the infusion tube body through a liquid medicine catheter. The inflatable air bag is additionally arranged to open the infusion tube body, the infusion tube body is sleeved with the liquid medicine spraying bag, the liquid medicine can be evenly sprayed into the bladder, in addition, by means of the pagoda connector, chemotherapy medicine is prevented from being sprayed outwards, medicine waste is avoided, and meanwhile chemotherapy medicine pollution is avoided. By injecting air for pressurization, the medicine can form a spray shape through the conical valve type sprinkling holes, gas and liquid are blended to increase the contact area with the bladder mucosa, and the purpose of treatment is effectively achieved. And after the medicine injection is finished, certain gas is injected, so that the medicine in the perfusion apparatus reaches the bladder, and the medicine treatment effect is played to the maximum extent.

According to the breast cancer prediction model construction system based on the MRI image and the storage medium provided by the invention, the model for predicting the neoadjuvant chemotherapy pathological alleviation condition and prognosis of the breast cancer patient is constructed by combining the dynamic change of the blood vessel characteristics and the clinical pathological characteristics, so that the system has relatively high accuracy and clinical practicability, and is suitable for popularization and application. And making of an individualized adjuvant therapy scheme is facilitated. The method can early predict breast pathology remission and long-term prognosis, and can early and accurately predict neoadjuvant chemotherapy curative effect and long-term prognosis of breast cancer patients. The model predicts whether a patient can achieve complete relieving of breast pathology or not by analyzing changes of breast tumor blood vessel characteristics in the chemotherapy process and correlation with clinical factors, and further predicts the recurrence-free lifetime of the patient, so that a reference basis is provided for individualized treatment.

The utility model relates to an abdominal cavity hyperthermic perfusion chemotherapy device which comprises an abdominal pressure belt and a perfusion assembly, and the perfusion assembly comprises a drainage tube which penetrates through the abdominal pressure belt and is detachably connected with the abdominal pressure belt; a partition plate is arranged in the drainage tube along the longitudinal axis, the partition plate can divide an inner tube cavity of the drainage tube into an independent perfusion cavity and an independent extraction cavity, a plurality of ribs extending in the length direction of the drainage tube are arranged on the inner tube wall of the perfusion cavity and the inner tube wall of the extraction cavity, and the ribs form a first blank section in the perfusion cavity in a vacancy reserving mode. A second blank section is formed in the extraction cavity, a first baffle and a second baffle which can be opened and closed are arranged at the far end of the partition plate, and when the two baffles are closed, the first baffle can be limited in the first blank section so as to block an outlet of the perfusion cavity; and the second baffle can be limited in the second blank section to block the outlet of the extraction cavity.

The invention discloses application of circFAM126A in preparation of a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the technical field of molecular biology. According to the application disclosed by the invention, by constructing a lentivirus for targeted interference of novel circFAM126A and transfecting gastric cancer cells, it is proved that the lentivirus carrying a specific interference sequence can stably knock down circFAM126A expression in the gastric cancer cells, the drug resistance of the gastric cancer cells to oxaliplatin is effectively reversed, the tumor cell death effect induced by chemotherapeutic drugs is remarkably enhanced, and the tumor cell death effect is remarkably improved. Meanwhile, the proliferation and clone formation capability of gastric cancer cells is inhibited. Meanwhile, it is found that circFAM126A is highly expressed in oxaliplatin-resistant gastric cancer cells and is in positive correlation with poor prognosis of gastric cancer patients, a detection reagent aiming at circFAM126A can be used for auxiliary diagnosis of gastric cancer prognosis conditions, and the drug resistance degree of the gastric cancer cells to oxaliplatin can be evaluated by detecting the expression level of circFAM126A.

The invention discloses a platinum (IV)-pirfenidone compound prodrug, a preparation method and microenvironment remodeling anti-tumor application, and belongs to the field of medical technology and drug synthesis. A series of molecules are characterized by being platinum prodrugs modified by pirfenidone derivatives. The synthesis method sequentially comprises the following steps: oxidizing platinum drugs, modifying hydroxyl groups, and introducing pirfenidone derivatives through esterification reaction. A series of molecules are reduced into Pt (II) drugs at the focus to kill cancer cells, and meanwhile, the released pirfenidone derivative can remodel the tumor microenvironment. The platinum prodrug disclosed by the invention not only has excellent cancer cell killing ability, but also is relatively low in drug resistance and excellent in safety, can trigger immunogenic cell death, and is a brand new chemotherapy-immunotherapy method. A series of molecules are convenient to synthesize, the preparation process is simple, and the amphipathicity is excellent, the anti-cancer capability is excellent, the drug resistance and toxicity are low, and the clinical application prospect is good.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug- resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.

The invention relates to the technical field of medical care, and discloses a chemotherapy nursing device for medical oncology, comprising: an infusion seat for infusion; the lower annular plate is arranged at the top of the infusion seat; the upper ring plate is arranged at the top of the lower ring plate; the diaphragm is arranged in the upper annular plate; the inner sealing piece is arranged on the inner side of the lower annular plate and used for connecting the lower annular plate with the inner wall of the upper annular plate; and the outer sealing piece is arranged on the outer side of the lower annular plate. Positioning of the upper annular plate by a positioning assembly is omitted, so that the position of the upper annular plate can be adjusted, the position of the diaphragm can be adjusted, the central needle inserting position of the diaphragm can avoid a disease skin area, normal needle inserting can be guaranteed, the upper annular plate is heated through a heating ring, and the needle inserting efficiency is improved. And heat is transferred to the skin, so that the skin cannot be tightened due to coldness, and the upper ring plate can be easily pushed subsequently.